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ABSTRACT 
Objective 
Apolipoprotein E ε4  (APOE ε4) is a strong genetic risk factor of Alzheimer’s disease (AD). 
The mechanism underlying AD pathogenesis in APOE ε4 carriers remains unclear. We 
 
hypothesize that apoE isoforms (encoded by different APOE alleles) have differential effects 
on synaptic function. 
Methods 
A total of 399 Alzheimer Disease Neuroimaging Initiative (ADNI) subjects with normal 
cognition, mild cognitive impairment (MCI) and AD were studied.  We compared the levels 
of CSF neurogranin (Ng), a postsynaptic maker, between APOE ε4 carriers and non-carriers. 
We examined associations of age, education, gender, and CSF amyloid beta 42 (Aβ42), total 
tau (t-tau), and phosphorylated tau (p-tau) with Ng levels.  
Results 
Neurogranin levels were significantly higher in APOE ε4 carriers with MCI, as compared to 
APOE ε4 non-carriers with MCI (?) (569.27±32.83 v.s. 403.03±37.23, p=0.01).  There was 
no difference in the levels of Ng between the APOE ε4 carriers and APOE ε4 non-carriers 
with AD (541.34±37.02 v.s. 575.05±72.76, p=0.57). The levels of CSF Ng were correlated 
with MMSE (r=-0.16, p=0.001), levels of tau (r=0.76, p<0.0001), p-tau (r=0.61, p<0.0001) 
and amyloid 42 (r=-0.34, p<0.0001). The levels of CSF Ng were significantly associated 
with APOE ε4 independent of age, education and gender.  
Interpretation 
Significantly elevated CSF Ng levels in APOE ε4 carriers with MCI may reflect synaptic 
injury associated with early cognitive impairment. Associations of CSF Ng with Aβ42 and 
tau support the role of synaptic dysfunction in AD. Neurogranin may be an early clinical 
biomarker of AD for disease diagnosis and timing of intervention in APOE ε4 carriers. 
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INTRODUCTION 
 
Alzheimer’s disease (AD) is the most common form of dementia. Pathologically, it is 
characterized by extracellular amyloid deposition and intracellular accumulation of 
hyperphosphorylated tau protein in the patient’s brain. In late-onset AD, over half of all AD 
cases are associated with the APOE ε4 genotype, highlighting the important role of APOE ε4 
in AD pathogenesis1.  
APOE ε4 carriers with AD or amnestic mild cognitive impairment (aMCI), a prodromal 
stage of AD, have lower beta β-amyloid 42 (Aβ42), elevated total tau (t-tau) and phospho-
tau (p-tau) in cerebrospinal fluid (CSF), compared to APOE ε4 non-carriers2.  Structural 
magnetic resonance imaging (MRI) studies, independent of CSF study, have shown that 
APOE ε4 carriers with AD and MCI have more severe brain atrophy in the parietal and 
temporal lobe and hippocampus, compared to APOE ε4 non-carriers3.  Taken together, it is 
suggested that the APOE ε4 genotype has multiple effects on the brain metabolism and 
structure.  
Currently, the exact mechanism by which the APOE ε4 genotype contributes to the early 
onset and rapid progression of the disease remains unclear.  Although the APOE ε4 genotype 
affects amyloid metabolism, a lack of consistent association between amyloid deposition 
and cognitive impairment suggests that other pathophysiological factors may be involved in 
cognitive decline seen among APOE ε4 carriers.    
Synaptic dysfunction has been postulated as a central mechanism underlying the 
cognitive impairment in AD4.  Additionally, neuropathological studies demonstrate that 
post-synaptic components are damaged in AD5. Neurogranin (Ng) is a post-synaptic 
protein, which is highly expressed in hippocampus and involved in memory consolidation6.  
Kvartsberg et al. report that Ng is markedly elevated in CSF of patients with AD and MCI, 
indicating that Ng can be a biological marker reflecting synaptic integrity7. We hypothesize 
that APOE ε4 has detrimental effects on synaptic function, leading to the elevated level of 
Ng, which may in turn contribute to the cognitive impairment in the APOE ε4 carriers of 
AD.  
To investigate the effect of APOE ε4 on CSF Ng, CSF Ng levels were examined in 
subjects with normal cognition, MCI and AD from the ADNI dataset.  We compared the 
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levels of CSF Ng between APOE ε4 carriers and APOE ε4 non-carriers among these 
subjects. We examined the gene dose effect of APOE ε4 on the levels of the CSF Ng.  We 
examined the correlation between Ng and mini mental state examination (MMSE), CSF 
amyloid, tau protein, and phospho-tau protein. Finally, we analyzed the association of 
APOE ε4 with Ng by controlling for age, education, gender, clinical diagnosis and CSF 
Aβ42, t-tau and p-tau. 
 
MATERIALS AND METHODS 
ADNI Study 
Data used in the preparation of this article were obtained from the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 
2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. 
The primary goal of ADNI has been to test whether serial magnetic resonance imaging 
(MRI), positron emission tomography (PET), other biological markers, and clinical and 
neuropsychological assessment can be combined to measure the progression of mild 
cognitive impairment (MCI) and early Alzheimer’s disease (AD).  In our study, the subjects 
with an initial analysis of Ng were included. Institutional review board approval is obtained 
at each ADNI site, and informed consent is obtained from each participant or authorized 
representative. Demographic information is extracted from the ADNI database. In this 
study, there are 111 subjects with normal cognition, 193 subjects with MCI, and 95 subjects 
with AD.  
CSF Analyses 
Quantification of  neurogranin (Ng) in CSF: 
The levels of the CSF Ng were determined at the Clinical Neurochemistry Laboratory, 
University of Gothenburg, Sweden, results are available from ADNI database. As described 
previously in detail (REF=Kvartsberg), CSF Ng was analyzed by electrochemi-
luminescence technology (Meso Scale Discovery, Gaithersburg, Maryland, USA) using Ng 
7, which is a monocloncal antibody specific for Ng, as coating antibody and polyclonal Ng 
anti-rabbit (ab 23570, Upstate) as a detector antibody. Values are given as pg/mL. 
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Quantification of amyloid 42, total tau and phospho-tau in CSF: 
The levels of amyloid 42, total tau (T-tau) and phosphorylated tau (P-tau) were analyzed by 
Leslie M Shaw and John Q Trojanowski’s group, Department of Pathology & Laboratory 
Medicine and Center for Neurodegenerative Diseases Research, Perelman School of 
Medicine University of Pennsylvania. The results are available from ADNI database 
(UPENN-Biomarker data [ADNI1]).  As described previously (REF = Shaw et al, Ann 
Neurol 2009;65:403-413), the xMAP Luminex platform and Innogenetics/Fujirebio AlzBio3 
immunoassay kits were used following the SOP in place at the UPenn/ADNI Biomarker 
Laboratory, according to the kit manufacturer’s instructions Acceptance criteria as 
documented in the UPenn/ADNI Biomarker Laboratory SOP were followed for these 
analyses. Individual sample results were acceptable in all cases except where noted and 
those are reported as “NA” in the CSV file “BIOMARK5”. Linear regression analyses 
(Passing-Bablock) were performed for Aβ1-42 and t-tau comparing CSF concentration 
results obtained.  
 
APOE Alleles genotyping: 
APOE (gene map locus 19q13.2) genotypes of the study subjects were obtained from ADNI 
database (adni.loni.usc.edu).  
 
Statistical Analysis 
The F test was used to examine the differences in continuous variables and the χ2 test was 
used to compare the frequencies of categorical variables among control, MCI and AD 
groups. Statistically significant results for individual variables were followed by post-hoc 
pairwise comparisons with the Tukey’s HSD method. To examine the association between 
APOE ε4 genotype and Ng levels, a series of linear regression models were constructed:  
model 1 was unadjusted; model 2 was adjusted for age, sex and education attainment; model 
3 was additionally adjusted for cognition status; and model 4 was additionally adjusted for 
biomarker Tau and amyloid 42 levels. All data analyses were performed with SAS statistical 
software version 9.3 (SAS institute, Cary, NC) and the level of statistical significance was 
set at p < 0.05. 
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RESULTS 
 
Demographic information of study subjects: 
Table 1 depicts the demographic information of the subjects. There were 111 subjects with 
normal cognition, 193 subjects with MCI, and 95 subjects with AD. There were no 
significant differences in age and education across the three groups. As expected, there was 
a significant difference in MMSE scores across the three groups, (P< 0.001). The mean 
MMSE score in the patients with AD was 24 ± 2, consistent with mild AD dementia (Table 
1).  In agreement with the previous findings, over 50% of the subjects with MCI and AD 
were APOE ε4 carriers8. There was a significant difference in CSF Aβ42, t-tau, and p-tau 
across the three groups.  Consistent with the previous findings, the subjects with AD had the 
lowest CSF amyloid 42, highest total tau protein and phospho-tau protein9.  
 
Significantly greater levels of the CSF Ng in the APOE ε4 carriers: 
To study Ng in AD, the levels of CSF Ng were analyzed among the three groups: control, 
MCI, and AD.  Results showed that the CSF Ng was significantly higher in the subjects with 
AD, followed by MCI, then normal control (p<0.001) (Figure 1). The results are consistent 
with the previous finding reported by Kvartsberg et al7. To examine the association of 
APOE ε4 genotype with the CSF Ng, the levels of CSF Ng were compared between APOE 
ε4 carriers and APOE ε4 non-carriers of the three groups.  In the normal control group, 
APOE ε4 carriers had a tendency to have higher CSF Ng, compared to APOE ε4 non-
carriers, although the difference only approached statistical significance (p=0.06) (Figure 2a).  
In the MCI group, APOE ε4 carriers had significantly higher levels of CSF Ng, compared to 
that of APOE ε4 non-carriers  (p=0.001). In the AD group, there was no statistical difference 
in the levels of CSF Ng between APOE ε4 carriers and APOE ε4 non-carriers (p=0.57). To 
confirm the effect of APOE ε4 in CSF Ng, the gene dose effect of APOE ε4 in the levels of 
the CSF Ng was analyzed. Across the entire sample it was shown that the levels of CSF Ng 
were increased in a gene dose-dependent manner (heterozygous APOE ε4 v.s. homozygous 
APOE ε4), confirming that APOE ε4 is directly associated with the levels of Ng (Figure 2b).   
 
Correlation of Ng with MMSE, amyloid 42, total tau, and phospho-tau:  
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To understand the mechanism underlying the elevated Ng in the APOE ε4 carriers, the 
correlation between Ng and global cognition was analyzed in this cohort (Table 2). An 
inverse correlation between Ng and MMSE scores was found (r= -0.16, p=0.001). In 
addition, an inverse relationship between Ng and amyloid 42 was observed. (r = -0.34, 
p<0.0001). We further analyzed the relationship between Ng and tau protein. The strong 
positive correlation between Ng and total-tau protein, and phosph-tau protein was observed 
(r=0.71, p< 0.0001; r=0.67, p< 0.0001 respectively).  
 
Association of Ng with APOE ε4: 
To further define the relationship between APOE ε4 and Ng, the association of Ng with 
APOE genotype, with or without controlling other factors, was analyzed using a generalized 
linear model (Table 3). Ng was significantly associated with APOE ε4 (standardized β = 
0.22 (0.05); p<0.0001) without controlling other factors (Model 1). A significant association 
of Ng with APOE ε4 was found after adjusting for age, education, and gender (β = 
0.21(0.05); p<0.0001) (Model 2).  We further confirmed that Ng is significantly associated 
with APOE ε4 after adjusting for age, education, gender, and diagnosis (β = 0.15 (0.05); 
p=0.0029) (Model 3). Finally, we examined the association of Ng with AD CSF biomarkers. 
We found that the association of Ng with APOE ε4 was no longer present after controlling 
for CSF amyloid and tau protein (β = 0.01 (0.04); p=0.84) (Model 4).   
 
DISCUSSION 
In this study, the levels of CSF neurogranin (Ng) were significantly greater in APOE ε4 
carriers with MCI, as compared to that of the APOE ε4 non-carriers, and a similar trend was 
found among controls. CSF Ng levels were increased in an APOE ε4 gene dose-dependent 
manner.  In contrast, there was no difference in the levels of Ng between APOE ε4 carriers 
and non-carriers with AD dementia. CSF Ng levels were correlated with MMSE, t-tau, p-tau 
and Aβ42. CSF Ng levels were significantly associated with APOE ε4 independent of age, 
education and gender.  
Although APOE ε4 has been reported as a strong risk factor of AD for decades, the 
mechanism underlying pathogenesis of AD in APOE ε4 carriers remains unclear.  Our 
findings provide clinical evidence that synaptic damage in the APOE ε4 carriers can be 
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detected at an early stage of AD. In the current study, 53 % of the MCI subjects and 71 % of 
the AD subjects were APOE ε4 carriers, highlighting the importance of the APOE ε4 
genotype in AD.  To our knowledge, this is the first report of increased CSF Ng among MCI 
APOE ε4 carriers compared with MCI APOE ε4 non-carriers.   
Higher levels of Ng were also observed among control APOE ε4 carriers as compared to 
APOE ε4 non-carriers, with the differences approaching statistical significance. Given the 
modest number of cognitively normal participants who were APOE positive, a larger number 
of APOE ε4 positive patients would have likely yielded more statistical power and resulted in 
statistically significant findings given the observed effect size. The effect of APOE ε4 in Ng 
is also shown to be gene dose dependent. The finding supports the previous study by Reiman 
and colleagues who reported that APOE ε4 gene dose is correlated with lower regional 
CMRgl10.   
There was no significant difference in CSF Ng concentrations between APOE ε4 
carriers and non-carriers with AD. These data suggest that increase in CSF Ng reflects an 
early event in the pathophysiological process of AD in APOE ε4 carriers and that synaptic 
dysfunction might be a mechanism contributing to the clinical phenotype already in pre-
dementia stages of the disease. This finding is consistent with a previous study reported by 
Kvartsberg et al.7.  In their MCI cohort, high CSF Ng levels were found to predict 
progression to dementia regardless of APOE genotype.  
Neurogranin, a post-synaptic protein, is implicated in the formation of long-term 
potentiation of synaptic plasticity. Ng knockout mice show severe deficits in visual-spatial 
learning. , Davidsson and Blennow found that the expression of Ng, along other synaptic 
proteins, is reduced in AD brains11. Chang reported that Ng mRNA is selectively detected in 
the dendrite and soma of neurons in the cerebral cortex and hippocampus12. In AD neo-
cortex tissue, Ng mRNA translocation to dendrites is reduced, while Ng mRNA 
translocation to dendrites is preserved in frontotemporal dementia12, 13.   Taken together, it is 
suggested that Ng might play an integral role in the cascade of neural events leading to AD.   
Since Ng reflects synaptic function in vivo, a prospective study with repeated CSF 
samplings examining Ng over the disease course in APOE ε4 carriers is likely to greatly 
enhance our understanding of AD pathogenesis.  
Regarding APOE genotype and synaptic function, animal studies show that apoE 
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isoforms encoded by different APOE alleles differentially regulate synaptic plasticity and 
repair14.  White et al. demonstrated that compensatory sprouting in association of 
synaptophysin and GAP-43 after entorhinal cortex lesion is impaired in transgenic mice 
expressing human apoE4, compared with apoE3 transgenic mice15. This indicates that the 
APOE ε4 genotype is involved in poor synaptic plasticity. APOE ε4 targeted replacement 
mice show reduced excitatory synaptic transmission and dendritic arborization, compared to 
the mice with APOE ε3 targeted replacement mice16. It indicates that APOE ε4 genotype 
modulates post-synaptic function.  Although mounting evidence shows the association of 
APOE genotype with synaptic function in animal models, the findings of APOE effect on 
synaptic function in human is limited.  Our study provides clinical in vivo evidence that the 
apoE isoforms may differentially regulate synaptic function in human subjects.  
In this study, we found that the levels of CSF Ng correlate with MMSE, CSF amyloid 
42, and tau protein. The strongest correlation was found between Ng and total tau protein, 
indicating a close relationship between synaptic injury and diffuse neuronal degeneration in 
AD, as tau pathology contributes more to synapse degeneration and resultant dementia17, 18.  
Although tau protein is primarily considered to be an axonal protein, recent studies show tau 
presents in postsynaptic terminals of non-demented human controls as well as AD cases19,20.  
Additional studies show that tau is important for targeting fyn kinase to the post-synaptic 
density21,22, 23. Further support for the involvement of tau in post-synaptic dysfunction was 
gained from studies showing that accumulation of P301L mutant tau in dendritic spines of 
cultured neurons is associated with disrupted synaptic transmission and altered 
neurotransmitter receptor composition of the post-synaptic density 24-27.  Taken together, our 
data suggest that tau protein and Ng might play a collective role in the post-synaptic 
compartment.  Aberrant function of tau and Ng protein induced by APOE ε4 may represent 
a critical event in the pathogenesis of AD.  
In this study, we also found a correlation between the CSF Ng and amyloid 42. 
While this may suggest that amyloid pathology is involved in the process of synaptic injury 
in the subjects with APOE ε4 genotype, another explanation is that this association merely 
reflects the association of amyloid 42 and tau in the CSF.  Indeed, when we controlled for 
levels of CSF tau, the association between amyloid and NG was no longer present. 
Relationship between amyloid and synaptic injury has been reported in several studies28,29. 
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Emerging evidence suggests that Aβ-induced synaptic dysfunction is dependent upon the 
elevation of cytoplasmic Ca2+ and NMDA receptor -mediated activity29-31.  This process 
results in dendritic spine loss. As Ng is localized in dendritic spine and involved in calcium 
mediated NMDA receptor activity, the association of Ng with amyloid-induced pathology 
should be further investigated. Although Kvartsberg et al. did not find a relationship 
between amyloid 42 and Ng7, this discrepancy might be attributable to differences in their 
study sample. 
The cross sectional design utilized in our study does not permit us to address the 
sequence of the events that may lead to cognitive impairment as a result of elevated Ng, 
decreased amyloid 42, and increased tau protein in CSF.  A longitudinal study to monitor 
the levels of the CSF Ng, amyloid 42, and tau protein in the APOE ε4 carrier is needed to 
provide much needed information pertaining to possible mechanisms underlying synaptic 
dysfunction in the APOE ε4 carriers of AD.  
In summary, we report that the levels of CSF Ng are significantly elevated in the APOE 
ε4 carriers who have MCI. These data indicate that that post-synaptic injury is an early 
pathological event in the APOE ε4 carriers. The levels of CSF Ng are correlated with 
MMSE, the levels of tau, p-tau  and amyloid 42. Independent of age, gender, and education, 
the levels of Ng are associated with APOE ε4 and clinical diagnosis. Association of Ng with 
APOE ε4 was no longer present after controlling for CSF amyloid and tau protein.  We 
believe the interaction among Ng, tau protein, and amyloid 42 might be an important 
mechanism underlying synaptic damage in the APOE ε4 carriers. Our study provides clinical 
evidence that APOE isoforms may have differential effects on the CSF Ng and that the 
synaptic damage associated with the APOE ε4 genotype might contribute to the clinical 
phenotype of early onset and rapid progression of the disease in the APOE ε4 carriers.  A 
limitation of this and all studies of association is that there may be other unknown mediating 
factors in early AD that may underlie observed correlations between Ng and other variables. 
There is no question that understanding the APOE ε4 effect in the pathogenesis of AD will 
significantly improve the diagnosis and treatment of AD.  
Further study is warranted to investigate whether the elevated CSF Ng represents a 
specific marker for post-synaptic damage in AD.  Nevertheless, a significant elevation of the 
CSF Ng in the early stage of AD in the APOE ε4 carriers provides a useful in vivo clinical 
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marker for diagnosis, timing of intervention, and monitor of AD in association with cognitive 
impairment.  
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Table and Figure legend 
Table 1 shows the demographic information of normal cognition, MCI and AD subjects. 
MCI, mild cognitive impairment; AD, Alzheimer’s disease 
 
Table 2 shows the correlation between CSF neurogranin and MMSE, total tau, phospho-tau 
and amyloid β 42. CSFNG, CSF neurogranin  
 
Table 3 shows the association of neurogranin with APOE ε4 adjusted for age, education, 
gender, clinical diagnosis, CSF tau and amyloid β 42.  
 
Figure 1 shows CSF neurogranin levels in the subjects with normal cognition, MCI and AD.  
MCI, mild cognitive impairment; AD, Alzheimer’s disease 
 
Figure 2 a. showing comparison of the CSF neurogranin levels in the APOE ε4 carriers and 
APOE ε4 non-carriers with normal cognition, MCI and AD.  b. showing the levels of CSF 
neurogranin are increased in a gene dose manner of APOE ε4. MCI, mild cognitive 
impairment; AD, Alzheimer’s disease 
 
 
